CytomX Therapeutics (CTMX) EBIT Margin (2014 - 2026)
CytomX Therapeutics (CTMX) posted EBIT Margin of 191.77% for Q1 2026, up 95.45% on a QoQ basis from 4212.97% in Q4 2025, and down 23620.0% year-over-year from N/an in Q1 2025.
CytomX Therapeutics (CTMX) EBIT Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics' EBIT Margin history runs 13 years deep, the most recent figure standing at 191.77% for Q1 2026.
- Quarterly EBIT Margin fell 23620.0% year-over-year to 191.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 181.92% (down 20629.0% YoY) and the FY2025 annual result came in at 29.35%, down 4745.0% from the prior year.
- EBIT Margin was 191.77% for Q1 2026 at CytomX Therapeutics, up from 4212.97% in the prior quarter.
- Across five years, EBIT Margin topped out at 46.41% in Q4 2024 and bottomed at 4212.97% in Q4 2025.
- A 5-year average of 324.05% and a median of 24.06% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin jumped 33061 bps — and 2025, when it plunged 425938 bps.
- CytomX Therapeutics' EBIT Margin stood at 47.25% in 2022, then jumped by 95 bps to 2.28% in 2023, then surged by 2138 bps to 46.41% in 2024, then plunged by 9178 bps to 4212.97% in 2025, then jumped by 95 bps to 191.77% in 2026.
- Business Quant data shows CTMX's EBIT Margin at 191.77% in Q1 2026, 4212.97% in Q4 2025, and 264.43% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | -191.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -191.77% |
| Dec 31, 2025 | -4,212.97% |
| Sep 30, 2025 | -264.43% |
| Jun 30, 2025 | -6.89% |
| Mar 31, 2025 | 44.43% |
| Dec 31, 2024 | 46.41% |
| Sep 30, 2024 | 12.30% |
| Jun 30, 2024 | -33.65% |
| Mar 31, 2024 | 28.11% |
| Dec 31, 2023 | -2.28% |
| Sep 30, 2023 | 11.84% |
| Jun 30, 2023 | -13.54% |
| Mar 31, 2023 | -24.06% |
| Dec 31, 2022 | -47.25% |
| Sep 30, 2022 | -266.53% |
| Jun 30, 2022 | -233.83% |
| Mar 31, 2022 | -354.67% |
| Dec 31, 2021 | -313.54% |
| Sep 30, 2021 | -337.78% |
| Jun 30, 2021 | -303.56% |